Veristat
Veristat is recorded as a service provider in 10 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 10 of 10 trials · Latest update first
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
Sponsor Mirati Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression ≥1%
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease (ADEPT-2)
Sponsor Karuna Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, First-in-Human, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia
Sponsor Hemab ApS
- Start (EU)
- Latest update
- Estimated end
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimer’s Disease (ADEPT-3)
Sponsor Karuna Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies
Sponsor Cellcentric Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK)
Sponsor Travere Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer
Sponsor Achilles Therapeutics UK Limited
- Start (EU)
- Latest update
- Estimated end
An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with metastatic or recurrent melanoma
Sponsor Achilles Therapeutics UK Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Veristat?
The 2026-10-09 snapshot links Veristat to 10 distinct CTIS trials. Recorded services include Statistical analysis, Electronic data capture, Data management, Data monitoring committee output production, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Veristat?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Cardiology, Gastroenterology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Veristat conducted?
The linked trials record locations in 20 countries, including Spain, Belgium, Germany, France, Italy. These are trial locations, not confirmed office locations or countries where Veristat delivered services.
What can this page tell me about Veristat's trial experience?
Browse 10 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Veristat. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Veristat LLC